Search All Tech Briefings

Search technology briefings produced by NIHR Innovation Observatory. These are short reports on new or repurposed medicines that we have already sent to our stakeholders. Only those technologies (medicines) that are within the scope of our stakeholders will have a technology briefing available. Search our technology briefings by intervention (drug or device), specific indication (disease or condition), or general therapeutic area.

| 55 Results

Clear All Filters

Title	Intervention	Indication	Therapeutic Area	Year	Actions
Guselkumab for treating chronic plaque psoriasis in children aged 6 to 17 years	Guselkumab (Tremfya; CNTO-1959)	Plaque psoriasis	Dermatology	2024	View \| Download
Guselkumab for active psoriatic arthritis	Guselkumab (Tremfya; CNTO-1959)	Psoriatic arthritis	Dermatology , Rheumatology	2019	View \| Download
Granexin Gel for Diabetic Foot Ulcers	Granexin (ACT-1)	Diabetic foot ulcer (DFU)	Cardiovascular System , Dermatology , Endocrine Nutritional and Metabolic Disorders	2018	View \| Download
Efgartigimod alfa for treating pemphigus vulgaris or pemphigus foliaceus	Efgartigimod alfa (ARGX-113)	Pemphigus foliaceus , Pemphigus vulgaris	Dermatology , Immunology	2023	View \| Download
ECCS-50 (Cytori stem cell therapy) for moderate to severe hand dysfunction due to Scleroderma	ECCS-50 (Adipose-derived stem and regenerative cells (ADRCs))	Hand dysfunction	Dermatology , Musculoskeletal System	2017	View \| Download
Dupilumab for treating Prurigo Nodularis	Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893)	Prurigo nodularis (PN)	Dermatology	2021	View \| Download
Dupilumab for treating Chronic Spontaneous Urticaria in people aged 12 years and older after 1 previous treatment	Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893)	Chronic spontaneous urticaria (CSU)	Dermatology	2021	View \| Download
Dupilumab for treating bullous pemphigoid	Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893)	Bullous pemphigoid	Dermatology	2024	View \| Download
Dupilumab for children aged 6 to less than 12 years with severe atopic dermatitis	Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893)	Atopic dermatitis	Dermatology	2019	View \| Download
Dupilumab for Children Aged 12 Years to 17 Years with Moderate to Severe Atopic Dermatitis	Dupilumab (Dupixent; REGN-668; SAR-231893; REGN668; SAR231893)	Atopic dermatitis	Dermatology	2018	View \| Download